Source: Government of Sweden
After two years of negotiations, EU Member States have agreed on a proposal for a revised pharmaceutical legislation in Europe. The process has met many obstacles along the way and the countries’ positions have been far apart on many fundamental issues, not least in regard to data protection issues and incentives for the development of priority antimicrobials.